Clinical Trial Update: Open-Label Extension Study for Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001 [Phase 1]

View source ↗

Summary

An open-label extension study (AK006-001) for subjects with H1 antihistamine-refractory chronic spontaneous urticaria has completed Phase 1.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• AK006

Snippet

Sponsor: Allakos Inc. | Conditions: Chronic Spontaneous Urticaria | Phase 1 | Status: COMPLETED